Zobrazeno 1 - 10 of 281 pro vyhledávání: '"M. Litschgi"'
5
GnRH-Analoga-Therapie bei aggressivem Angiomyxom - eine Therapieoption
Autor: A. Markus, M. Eberhard, M. Litschgi
Publikováno v: Geburtshilfe und Frauenheilkunde. 64:76-79
Aggressive angiomyxoma is a rare tumor of the soft tissue, which predominantly occurs in the pelvic and genital area. Angiomyxoma has a strong tendency to slow and locally destructive growth without metastases and with high local recurrence. The tumo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9c94e2900a29d5365558bc6ee57d6de
https://doi.org/10.1055/s-2003-44702
Zobrazit plný text záznamu
6
Vitex Agnus-Castus extract (Ze 440) improves symptoms in women with menstrual cycle irregularities
Autor: U. E. Gasser, S. Nebel, M. Litschgi, C. Zahner, R. Eltbogen
Publikováno v: Planta Medica. 80
Study Aims • To evaluate the effects of Ze 440 in women suffering from menstrual cycle irregularities (MCIs), such as polymenorrhoea, oligomenorrhoea and amenorrhoea. • To assess the effect of Ze 440 on other symptoms related to menstrual bleedin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97afd932d0a17b3137d5407a1c81ce70
https://doi.org/10.1055/s-0034-1394507
Zobrazit plný text záznamu
7
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
Autor: Willy Kueng, J L Roesel, J M Schlaeppi, M Litschgi, M Zuber, Christopher C. Benz, Heinz Mueller, Serenella Eppenberger-Castori, Manfred Schmitt, John A. Foekens, Urs Eppenberger, Alex Matter, K Luescher
Publikováno v: Journal of Clinical Oncology, 16(9), 3129-3136. American Society of Clinical Oncology
PURPOSE To compare the prognostic impact of tumor angiogenesis factors (vascular endothelial growth factor [VEGF], angiogenin, and basic fibroblast growth factor [bFGF]), tumor proteolysis factors (urokinase-type plasminogen activator [uPA] and plasm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5d2602bd02879e80659bdbbf7057f37
https://doi.org/10.1200/jco.1998.16.9.3129
Zobrazit plný text záznamu
8
Recommendations for raloxifene use in daily clinical practice in the Swiss setting
Autor: Olivier Lamy, M. Litschgi, Kurt Lippuner, Bruno Imthurn, Petra Stute, K. Schiessl, F. Luzuy, P. A. Buchard, Martin Birkhäuser, C. De Geyter
Publikováno v: Lippuner, Kurt; Buchard, P A; De Geyter, C; Imthurn, B; Lamy, O; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P; Birkhäuser, M (2012). Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European spine journal, 21(12), pp. 2407-17. Berlin: Springer-Verlag 10.1007/s00586-012-2404-y
Background/aim: Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive br
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1caafdb98af07585f02e7158bac3310
https://pubmed.ncbi.nlm.nih.gov/22739699
Zobrazit plný text záznamu
10
[Surveillance of hormone replacement therapy]
Autor: A, Campana, M, Litschgi, M, Birkhäuser, M, Mall-Häfeli, H, Welti, P J, Keller
Publikováno v: Schweizerische medizinische Wochenschrift. 127(43)
The prescription of hormone replacement therapy (HRT) requires a pretherapeutic evaluation and an ongoing surveillance during treatment. Pretherapeutic evaluation identifies the indications and contraindications to HRT. It includes a clinical examina
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bc7bdddb8a211b984d14f97b4ab12347
https://pubmed.ncbi.nlm.nih.gov/9446198
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje